Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 12/20 | 0.38 |
| ▸ | JUN | P05412 | 5/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.38 |
| ▸ | RELA | Q04206 | 5/20 | 0.38 |
| ▸ | XPO1 | O14980 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ATF1 | P18846 | 8/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23330662 | 0.87 | SMN1; SMN2 (0.41) | NFKB1JUNNFKB2RELASMN1; SMN2 | |
| SCHEMBL23330663 | 0.82 | SMN1; SMN2 (0.34) | NFKB1JUNNFKB2RELAXPO1 | |
| SCHEMBL19114853 | 0.79 | SMN1; SMN2 (0.44) | NFKB1JUNNFKB2RELAXPO1 | |
| SCHEMBL23331258 | 0.78 | PTK2 (0.43) | NFKB1JUNNFKB2RELAKDM4E | |
| SCHEMBL17111799 | 0.76 | NFKB1 (0.40) | NFKB1JUNNFKB2RELAXPO1 | |
| SCHEMBL17385135 | 0.74 | MEN1 (0.44) | NFKB1JUNNFKB2RELASMN1; SMN2 | |
| SCHEMBL17373087 | 0.74 | NFKB1 (0.46) | NFKB1JUNNFKB2RELAXPO1 | |
| SCHEMBL23330674 | 0.74 | ALDH1A1 (0.48) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3548542 | 0.71 | BTK (0.49) | — | |
| SCHEMBL2074438 | 0.71 | GAA (0.42) | SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| WO-2021083380-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, CYP4A11, HSD11B1 | NFKB1 2285/4885JUN 3386/4885NFKB2 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.